Skip to main content

Table 1 Possible patient conditions and their corresponding actions from the guidelines

From: Using data mining techniques to explore physicians' therapeutic decisions when clinical guidelines do not provide recommendations: methods and example for type 2 diabetes

  

Conditions

Actions

Profile #

Number of patients

Acute symptoms

HbA1c (%)

Ongoing type of treatment

BMI* (Kg/m2)

Renal insufficiency

Elderly

Type of treatment

Pharmaco-therapeutic class

International non proprietary name

Dose

1

2

Yes

Any

Any

Any

Any

Any

Insulin therapy

Insulin

NM***

NM***

2

16

No

≤ 6.5

Any

Any

Any

Any

The same as ongoing treatment

The same as ongoing treatment

The same as ongoing treatment

The same as ongoing treatment

3

7

No

Between 6.6 and 8

Diet and Exercise

Any

Any

Any

Evaluate risk-benefit of continuing or changing the treatment

NM***

NM***

NM***

4

51

No

Between 6.6 and 8

Monotherapy

Any

Any

Any

Evaluate risk-benefit versus of continuing or changing the treatment

NM***

NM***

NM***

5

59

No

Between 6.6 and 8

Bitherapy

Any

Any

Any

NM***

NM***

NM***

NM***

6

16

No

Between 6.6 and 8

Tritherapy

Any

Any

Any

NM***

NM***

NM***

NM***

7

84

No

Between 6.6 and 8

Insulin [+OAD]**

Any

Any

Any

NM***

NM***

NM***

NM***

8

2

No

>8

Diet and Exercise

Any, other than "BMI ≥ 28 and no renal insufficiency"

No

Monotherapy

Any

NM***

NM***

9

1

No

>8

Diet and Exercise

Any, other than "BMI ≥ 28 and no renal insufficiency"

Yes

Monotherapy

Any, other than long acting sulfonylurea

NM***

NM***

10

2

No

>8

Diet and Exercise

≥ 28

No

Any

Monotherapy

Biguanides

Metformine

NM***

11

24

No

>8

Oral monotherapy not at maximum dose

Any

Any

Any

Oral monotherapy

The same as ongoing treatment

NM***

Increase dose until reaching the maximum tolerated

12

1

No

>8

Oral monotherapy at maximum dose

Any

Any

Any

Oral bitherapy

NM***

NM***

NM***

13

39

No

>8

Oral bitherapy with any combination other than "Oral bitherapy with biguanides and sulfonylurea at maximum dose"

Any

Any

Any

Oral bitherapy

Biguanides and sulfonylurea

NM***

NM***

14

18

No

>8

Oral bitherapy with biguanides and sulfonylurea at maximum dose

Any

Any

Any

Insulin [+OAD]**

Insulin [+OAD]**

NM***

NM***

15

18

No

>8

Oral tritherapy

Any

Any

Any

NM***

NM***

NM***

NM***

16

123

No

>8

Insulin [+OAD]**

Any

Any

Any

NM***

NM***

NM***

NM***

  1. * BMI: body mass index
  2. ** Insulin [+OAD]: insulin alone or with oral anti-diabetic drugs
  3. *** NM: not mentioned in the guidelines